ENXTPA:IPNPharmaceuticals
Assessing Ipsen (ENXTPA:IPN) Valuation After ICC Ruling Secures Aesthetic Toxin Pipeline Ownership
The recent International Chamber of Commerce ruling in favor of Ipsen (ENXTPA:IPN) clarified ownership of its clinical stage aesthetic toxin assets, giving investors a clearer view of the company’s neuroscience pipeline and partnership arrangements.
See our latest analysis for Ipsen.
The ICC ruling and recent neurological conference updates come as Ipsen’s share price sits at €136.6, with a 30-day share price return of 13.83% and a 5-year total shareholder return of 101.08%. This suggests...